PTSD

Pervasip Releases Shareholder Letter

Retrieved on: 
Tuesday, January 4, 2022
MFDS, Biomass, Letter, Review, Research, Company, Depression, EBIDTA, Communication, Cannabinol, Intention, Autism, PTSD, Ministry of Food and Drug Safety, Perception, ADHD, Psilocybin, Legislation, Pain, News, ZAM, Ministry, Addiction, OTC Markets Group, KFDA, Risk management, Food

We already have significant progress on each front that we are excited to share over the coming months.

Key Points: 
  • We already have significant progress on each front that we are excited to share over the coming months.
  • With our investment in KRTL Biotech we are also starting to review the medicinal fungi market for unique product and other growth opportunities.
  • Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.
  • Further, any forward-looking information speaks only as of the date on which such statement is made.

DBK Announces Skybox Salute 2022, a Military and First Responder Gratitude Digital Event, During Hilton Grand Vacations Tournament of Champions

Retrieved on: 
Tuesday, January 4, 2022
People, Interest, DBK, Champion, Tragedy Assistance Program for Survivors, LPGA, Survivor, Food Service Solutions, Lake Nona Golf & Country Club, TAPS, General contractor, Gesture, General officer, Twitter, PTSD, Country club, 2014 LPGA Tour, Electricity, Woman, Instagram, Salute, Partnership, Hole, HVAC, GLOBE, Globe, Man, Veteran, Entertainment, Plumbing, Central Florida

This digital initiative takes place during the Hilton Grand Vacations Tournament of Champions on Jan. 20-23, 2022, and supports the military, first responders, and their families.

Key Points: 
  • This digital initiative takes place during the Hilton Grand Vacations Tournament of Champions on Jan. 20-23, 2022, and supports the military, first responders, and their families.
  • Messages and images tagged with #skyboxsalute will stream live online via DBK's social wall, viewed anywhere in the world, at godbk.com/skyboxsalute.
  • Now in its third year, the Salute to Service Skybox built by DBK provides a hospitality experience for select veterans, first responders, and Military Special Interest Groups during the Hilton Grand Vacations Tournament of Champions.
  • This year's partnership supports TAPS (Tragedy Assistance Program for Survivors) , PTSD Foundation of America , Pipe Hitter Foundation , and Mission 22 .

Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Tuesday, January 4, 2022
Surgery, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Chronic pain, MET, Severe acute respiratory syndrome coronavirus 2, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Central nervous system disease, Research, Lists of diseases, Epilepsy, Cancer, Conference, PTSD, CBD, CEO, PIPE, FDA, Pain, Bupivacaine, CNS, Technology, Post-traumatic stress disorder, Pain management, RD, Virpax Pharmaceuticals, H.C. Wainwright & Co., VIRPAX PHARMACEUTICALS, H.C. WAINWRIGHT & CO.

Management will also be hosting virtual one-on-one meetings on Monday, January 10th and Tuesday, January 11th.

Key Points: 
  • Management will also be hosting virtual one-on-one meetings on Monday, January 10th and Tuesday, January 11th.
  • Event: Virpax Pharma Presentation at the H.C. Wainwright BioConnect Virtual Conference
    Time: On Demand from 7:00 a.m.
  • ET daily
    For more information on the H.C. Wainwright BioConnect Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to [email protected] or call (212) 661-2231.
  • Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery.

ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Tuesday, January 4, 2022
Research, FDA, Clinical Trials, Other Health, Biotechnology, Alternative Medicine, Pharmaceutical, Health, Science, Other Science, Opioid use disorder, Clinical trial, Trial of the century, FDA, UCLA, Medicine, Cannabinoid, PTSD, Behavior, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, National Institute, Pharmacology, LDS, IND, Research, Opioid, University, NIDA, Investigational New Drug, National Institute on Drug Abuse, Cannabidiol, Jane, Anxiety, Psychiatry, Pharmaceutical industry, Neuroscience, CBD, EU

The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.

Key Points: 
  • The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
  • (Clinical Trials.gov Identifier: NCT03787628 )
    The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic, said Dr. London.
  • With the IND approved we are now moving quickly to get the trial under way, said Dr. De La Garza.
  • ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD , Radiculopathic Pain , Anxiety and Opioid Use Disorder .

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Retrieved on: 
Tuesday, January 4, 2022
Safety, Emotion, South London and Maudsley NHS Foundation Trust, US Foods, Volunteering, SSRI, TRD, Institute, Institute of Psychiatry, Psychology and Neuroscience, Clinical trial, Psychology, FDA, DOI, PTSD, Journal of Psychopharmacology, III, CMPS, Female, Food, IIB, Psilocybin, Mental health, Male, Adult, Patient, Nasdaq, Journal, Thought, Pharmaceutical industry, Psychopharmacology, South London

The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteers.

Key Points: 
  • The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteers.
  • The participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29).
  • There were no serious adverse events and COMP360 psilocybin was found to be well-tolerated with no clinically-relevant negative effects on cognitive function.
  • Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: This study was an early part of our clinical development programme for COMP360 psilocybin therapy.

Sapandeep Khurana, MD, FAPA, DFAACAPis recognized by Continental Who's Who

Retrieved on: 
Monday, January 3, 2022
American, Reno 1868 FC, Bipolar disorder, Intensive outpatient program, AMA Foundation Leadership Award, APA International Humanitarian Award, Continental, Adolescence, Fellow, AMA, University, Touro University, New Oakland Child-Adolescent and Family Center, National Association Medical Staff Services, PTSD, American Psychiatric Association, Behavioural sciences, Fellows, PHP, Multimedia, Organization, Lists of diseases, American Academy, ADHD, Graduate, FAPA, RTC, Parent, Mental health, Life, Distinguished Fellow of the British Computer Society, Residential treatment center, IOP, Government Medical College, Thiruvananthapuram, Patient, ITIL, Mentorship, American Academy of Child and Adolescent Psychiatry, San Diego State University, Residential area, Cognitive behavioral therapy, Medicine, Adult, Teaching hospital, Child, Autism, MD, Psychiatry

LAS VEGAS, Jan. 3, 2022 /PRNewswire/ -- Sapandeep Khurana, MD, FAPA, DFAACAP, is being recognized by Continental Who's Who as a Trusted Psychiatrist for his exceptional work in the field of Child, Adolescent, and Adult Psychiatry.

Key Points: 
  • LAS VEGAS, Jan. 3, 2022 /PRNewswire/ -- Sapandeep Khurana, MD, FAPA, DFAACAP, is being recognized by Continental Who's Who as a Trusted Psychiatrist for his exceptional work in the field of Child, Adolescent, and Adult Psychiatry.
  • The group provides Psychiatry for Intensive Outpatient (IOP), Partial Hospitalization Program (PHP), and the Residential Treatment Center (RTC).
  • Dr. Khurana works with multiple organizations to resolve issues in relation to Mental Health Programming, Staffing, Service Delivery, Operations, and Management.
  • Dr. Khurana also teaches medical students, residents, and Fellows for the University of Nevada and Touro University.

Virtual Reality in Medical Market Size to Reach USD 3,309.9 Million in 2028 | Increasing Use of VR in Medical Marketing and Rising Prevalence of Diseases are Among Some Key Factors Driving Industry Growth, according to Emergen Research

Retrieved on: 
Monday, January 3, 2022
Attention, Medicine, Infection, COVID-19, Anxiety, Disease, Google Cardboard, Population, Anatomy, VRET, CAGR, Reality therapy, Generalized anxiety disorder, HTC Vive, Post-traumatic stress disorder, Method, MDD, Nightmare, Social anxiety disorder, PTSD, VR, Coronavirus, Perception, CPR, Partnership, Pain, Cardiopulmonary resuscitation, Virtual reality, Hospital, Prevalence, USD, Alphabet Inc., Microsoft, Depression, Adult, Therapy, Patient, Telehealth, Samsung Gear VR, Technology, Oculus Rift, Awareness, General Electric, Learning, Computer, GAD, Adoption, SAD, Pain management, Pharmaceutical industry, Healthcare, Video game console, BC

VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.

Key Points: 
  • VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.
  • Medical professionals can receive other beneficial training through VR, including learning about infectious disease control and human anatomy.
  • Technical limitations in various healthcare facilities associated with implementation of VR could hamper market revenue growth to some extent over the forecast period.
  • The global Virtual Reality (VR) in medical market size is expected to reach USD 3,975.0 Million in 2028 and register a revenue CAGR of 31.1% over forecast period.

Virtual Reality in Medical Market Size to Reach USD 3,309.9 Million in 2028 | Increasing Use of VR in Medical Marketing and Rising Prevalence of Diseases are Among Some Key Factors Driving Industry Growth, according to Emergen Research

Retrieved on: 
Monday, January 3, 2022
Attention, Medicine, Infection, COVID-19, Anxiety, Disease, Google Cardboard, Population, Anatomy, VRET, CAGR, Reality therapy, Generalized anxiety disorder, HTC Vive, Post-traumatic stress disorder, Method, MDD, Nightmare, Social anxiety disorder, PTSD, VR, Coronavirus, Perception, CPR, Partnership, Pain, Cardiopulmonary resuscitation, Virtual reality, Hospital, Prevalence, USD, Alphabet Inc., Microsoft, Depression, Adult, Therapy, Patient, Telehealth, Samsung Gear VR, Technology, Oculus Rift, Awareness, General Electric, Learning, Computer, GAD, Adoption, SAD, Pain management, Pharmaceutical industry, Healthcare, Video game console, BC

VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.

Key Points: 
  • VANCOUVER, BC, Jan. 3, 2022 /PRNewswire/ -- The global Virtual Reality in medical market size was USD 446.2 Million in 2020.
  • Medical professionals can receive other beneficial training through VR, including learning about infectious disease control and human anatomy.
  • Technical limitations in various healthcare facilities associated with implementation of VR could hamper market revenue growth to some extent over the forecast period.
  • The global Virtual Reality (VR) in medical market size is expected to reach USD 3,975.0 Million in 2028 and register a revenue CAGR of 31.1% over forecast period.

Headstrong Project Inc. Announces Two-Year Investment from The Harry and Jeanette Weinberg Foundation, Generating Greater Access to Mental Health Treatment for Service Members, Veterans, and Family Members in the Baltimore Area

Retrieved on: 
Monday, January 3, 2022
The Alvin Weinberg Foundation, Anxiety, Suicidal ideation, Communication, National Guard, Family, GLOBE, PTSD, Harry, Partnership, Foundation, Veteran, Employment, Organization, Mental health, Depression, Program, National Guard Health Affairs, District, Private practice, Industry, Medicine, Hospital, Risk management, Headstrong, United States Army

Over the last nine years, Headstrong has led an unprecedented effort to expand access to high-quality, community-based mental health resources for our US military members, veterans, and their families.

Key Points: 
  • Over the last nine years, Headstrong has led an unprecedented effort to expand access to high-quality, community-based mental health resources for our US military members, veterans, and their families.
  • Transition and mental health problems related to two decades of fighting have been magnified by the pandemic and its aftermath.
  • Headstrong will commit engagement efforts that fit the Baltimore landscape best to ensure the military and veteran community have rapid and seamless access to tailored effective mental health treatment.
  • Since its founding in 2012, Headstrong has provided mission-critical mental health care
    accessing equitable mental health care in America.

DipJar Helps Nonprofits Raise Millions in 2021

Retrieved on: 
Tuesday, December 28, 2021
LMC, Friends, Botanical garden, Recreation, Florida Botanical Gardens, Investor, Foundation, Veteran, Education, Pathfinder, Courageous, Technology, PTSD, Organic, Organization, Garden, Center, CEO, Animal, Management, Residential care, Atlantic Ocean, Autism, Selland Arena

BOSTON, Dec. 28, 2021 /PRNewswire/ -- DipJar , a giving technology platform, is applauding its customers on an outstanding and inspiring 2021.

Key Points: 
  • BOSTON, Dec. 28, 2021 /PRNewswire/ -- DipJar , a giving technology platform, is applauding its customers on an outstanding and inspiring 2021.
  • DipJar is pleased to support the important work being done by charities and nonprofits across the country."
  • Since 2018, DipJar has helped raise over $500,000 - including more than $140,000 in 2021 at the Center and events in the community.
  • So far in December, DipJar has helped nonprofits use their DipJars to raise substantial sums.